Results 131 to 140 of about 25,780 (241)

PP2A Activation as a Senotherapeutic in Neuroblastoma. [PDF]

Cancers (Basel)
Nazam N, Shirley SN, Opara JC, Manzoor S, Shaikh MG, Brown ML, Nande P, Eakes AM, Kaimari A, Leavenworth JW, Ohlmeyer M, Beierle EA.   +11 more
europepmc   +1 more source

Safety and Antitumor Activity of the Usnic Acid Derivative OL9-116, a TDP1 Inhibitor, as an Adjunctive Therapy in Combination with Topotecan. [PDF]

Int J Mol Sci
Kornienko TE, Zakharenko AL, Chernyshova IA, Chepanova AA, Dyrkheeva NS, Firsova AA, Rogachev AD, Luzina OA, Popova NA, Maksimova VP, Vlasova OA, Deryagina VP, Rodnyy AY, Salakhutdinov NF, Lavrik OI.   +14 more
europepmc   +1 more source

Mathematical models characterising the kinetics and dynamics of topotecan to account for drug resistance mechanisms [PDF]

This thesis describes the use of mathematical modelling in studying the kinetics and dynamics of the anti-cancer agent topotecan (TPT), a semi-synthetic derivative of the natural extract camptothecin (CPT), which has been found to act as an inhibitor ...
Atari, M. I. (Mohammed Isam)
core  

Artificial Intelligence-Guided Prioritization and Experimental Evaluation of Synergistic Target Combinations for Breast Cancer Therapy. [PDF]

Pharmaceuticals (Basel)
Feng C, Feng Q, She S, Yang R, Li M, Gong L, Rui M.   +6 more
europepmc   +1 more source

Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan. [PDF]

Front Immunol
Wang J, Jiang H, Niu J, Liu L, Wu Y, Shi J, Liu L, Yin S, Feng C, Zhang L, Yang M, Yi Z.   +11 more
europepmc   +1 more source

Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer. [PDF]

Exp Hematol Oncol
Chiappa M, Villa V, Sias F, Grasselli C, Sala L, Canesi S, Marabese M, Mason S, Dibitetto D, Fruscio R, Damia G.   +10 more
europepmc   +1 more source

Pars Plana Vitrectomy for Retinal Detachment or Vitreous Haemorrhage after Retinoblastoma Regression: A 20-Year Single-Centre Experience. [PDF]

Ocul Oncol Pathol
Rajan RP, V M, Kim U, Kannan NB, Ramasamy K, Sharma A.   +5 more
europepmc   +1 more source

Multi-Omics Identification of UBE2C as a Prognostic Biomarker and Therapeutic Target Linked to Topotecan Sensitivity in Cervical Cancer. [PDF]

Oncol Res
Raj EN, Li CJ, Cheng SH, Yong SB, Wen ZH, Chiang AJ.   +5 more
europepmc   +1 more source

Correction: Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850). [PDF]

Pharm Res
Kimura T, Okada K, Morohashi Y, Matsuda S, Kato Y, Mori M, Kato H, Matsumoto T, Shimoyama S.   +8 more
europepmc   +1 more source

Intra-arterial chemotherapy for retinoblastoma: a structured narrative review. [PDF]

World J Pediatr Surg
Ren YH, Kang D, Shi C, Sun W.
europepmc   +1 more source